Pharmaceutical Executive Daily: Henlius' Exclusive License Agreement with U-Mab Biopharma

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.

In today’s Pharmaceutical Executive Daily, Henlius enters a global exclusive licensing agreement with UMAb Biopharma for a potential best-in-class anti-IL-1RAP antibody, a new report highlights drugmakers raising list prices amid pricing agreements with the Trump administration, and Novartis urges governments to address mounting global trade policy challenges impacting the biopharmaceutical industry.

Henlius has entered a global exclusive license agreement with UMAb Biopharma for a monoclonal antibody targeting IL-1RAP, a pathway associated with inflammatory and autoimmune diseases. The asset is positioned as a potential best-in-class therapy, strengthening Henlius’ immunology pipeline while expanding its international development and commercialization ambitions.

Meanwhile, a new report indicates that multiple pharmaceutical companies have raised list prices despite participating in agreements with the Trump administration aimed at lowering drug costs. The findings underscore ongoing tension between pricing commitments and market dynamics, as manufacturers balance policy pressure with inflation, rebates, and supply chain costs.

In parallel, Novartis is calling on global governments to address rising trade barriers and policy fragmentation affecting the biopharmaceutical sector. The company warns that inconsistent trade rules and tariff pressures could disrupt supply chains, slow innovation, and ultimately limit patient access to medicines worldwide.

Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.